Peg L Asparaginase Injection (L-ASPARA)

About Peg L Asparaginase Injection (L-ASPARA)

Peg L-Asparaginase Injection (L-ASPARA) is an enzyme-based medication used primarily in the treatment of acute lymphoblastic leukemia (ALL), a type of cancer that affects the blood and bone marrow. It is a pegylated form of asparaginase, which means it has been chemically modified with polyethylene glycol (PEG) to extend its half-life in the body, allowing for less frequent administration compared to non-pegylated asparaginase.

How it works:

• Asparaginase works by breaking down asparagine, an amino acid that is essential for the growth and survival of leukemia cells. Many cancerous cells, especially those in leukemia, depend on asparagine for their growth.
• By depleting asparagine, Peg L-Asparaginase disrupts the cancer cells' ability to proliferate, effectively killing or preventing the growth of these abnormal cells.

Common uses:

• Acute lymphoblastic leukemia (ALL): It is often used as part of a chemotherapy regimen for treating ALL in both children and adults.
• It may also be used in combination with other chemotherapy agents to treat various types of leukemia or lymphomas.

Dosage and administration:

• Peg L-Asparaginase is typically administered through an intravenous (IV) injection or, in some cases, as an intramuscular (IM) injection.
• The dose and frequency depend on the specific treatment protocol and the patient's condition. Typically, it is given once every 1421 days as part of a multi-drug chemotherapy regimen.
• Infusion rates and procedures will be carefully managed by healthcare professionals, often in a hospital or specialized setting.

Possible side effects:

• Allergic reactions: Some patients may develop allergic reactions, ranging from mild symptoms (rash, fever) to severe reactions (anaphylaxis). Pre-medications like antihistamines or steroids may be given to reduce these risks.
• Liver function abnormalities: Asparaginase can affect liver enzymes, so liver function will be closely monitored during treatment.
• Pancreatitis: Inflammation of the pancreas can occur and requires careful monitoring.
• Blood clotting issues: Since asparaginase can affect clotting factors, blood clotting issues or bleeding may arise.
• Other side effects: Nausea, vomiting, fatigue, and changes in blood sugar levels may also occur.

Important considerations:

• Pre-treatment testing: Before starting Peg L-Asparaginase, liver function tests and allergy assessments are typically conducted.
• Hydration and monitoring: Close monitoring of kidney and liver function is necessary, as well as observation for allergic reactions.
• Pregnancy and breastfeeding: This medication is generally not recommended during pregnancy or breastfeeding unless absolutely necessary, as it can harm a developing fetus or infant.

Monitoring and follow-up:

• Regular blood tests (including liver and kidney function tests, blood counts) are necessary to ensure safe use.
• Treatment regimens are typically individualized, so close communication with the healthcare team is vital throughout therapy.

Advanced Therapy for Leukemia

L-ASPARA leverages recombinant DNA technology and PEGylation to deliver a potent and prolonged treatment for patients with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma. Its increased half-life ensures sustained therapeutic efficacy, minimizing the frequency of dosing and maximizing patient comfort during treatment.


Strict Quality and Safety Standards

Manufactured in compliance with pharmaceutical-grade specifications and CTD requirements, L-ASPARA is supplied as a sterile, lyophilized powder in glass vials. The product features detailed storage instructions and a comprehensive MSDS, ensuring safety, efficacy, and consistency for clinical and hospital use worldwide.